市场概况

The Nucleic Acid Based Therapeutics Market is poised for significant growth, with a projected expansion from USD 4.28 billion in 2022 兑美元 9.51 十亿 2029, reflecting a robust compound annual growth rate (复合年增长率) 的 11.6% during the forecast period of 2023-2029. This market primarily revolves around the development and utilization of nucleic acid therapeutics for the treatment of various diseases. Notable examples of nucleic acid-based therapeutics include aptamers, antisense oligonucleotides (ASOs), and small interfering RNAs (siRNAs), which are designed to specifically target and suppress disease-related genes. ASOs and siRNAs, in particular, have demonstrated their efficacy in silencing genes by interfering with mRNA translation and nuclear DNA transcription.

The demand for nucleic acid-based therapeutics has witnessed a significant surge, driven by their successful application in the treatment of COVID-19. Research has shown promising results in utilizing these therapeutics to suppress viral gene expression, offering potential avenues for combating viral infections. 全球范围, there are currently over 400 RNA-targeting drug development projects underway, indicating a strong growth trajectory for the market throughout the forecast period.

The increasing prevalence of genetic diseases necessitates the development of innovative treatment approaches, and nucleic acid-based therapeutics offer a promising solution by targeting and correcting abnormal gene expression. 此外, investments in healthcare infrastructure and research and development activities, along with collaborations between pharmaceutical companies and academic institutions, further drive market growth. The pharmaceutical industry’s focus on developing innovative biologics, including nucleic acid-based therapeutics, also contributes to the expansion of the market.

市场细分

The market is segmented based on product type, 应用, end-user, and geography.

Segmentation by Product Type
RNA interference (RNAi) and short interfering RNAs (siRNAs)
Antisense Oligonucleotides (ASOs)
其他的

Segmentation by Application
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
其他的

Segmentation by End-User
Hospitals and Clinics
Academic and Research Institutes

Segmentation by Geography
北美 – 美国, 加拿大, 墨西哥
欧洲 – 英国, 德国, 法国, 意大利, 西班牙, and Rest of Europe
亚太 – 中国, 日本, 印度, 澳大利亚, 韩国, and Rest of Asia-Pacific
拉美 – 巴西, 阿根廷, and Rest of Latin America
中东和非洲 – GCC, 南非, and Rest of Middle East and Africa

Antisense oligonucleotides (ASOs) selectively bind to specific mRNA sequences, degrading or inhibiting their translation into protein. ASOs show promise for treating genetic disorders, 传染性疾病, and cancer. Approved ASO therapies like Spinraza, Exondys51, Onpattro, and Tegsedi demonstrate this approach’s success. The ASOs segment is expected to grow due to increased demand, 右&D activities, and new product introductions. Business strategies like partnerships and acquisitions drive growth, resulting in the availability of more ASO products and increased company activities.

North America is expected to hold a significant market share due to growing research on nucleic acid-based therapies, increasing prevalence of genetic and chronic disorders, and rising investments in research and development. The demand for nucleic acid-based therapies is driven by the prevalence of autoimmune diseases and the burden of cancer. Market growth is further supported by innovative product launches, approvals, 伙伴关系, 收购, expansions, and collaborations in the region.

Competitive Landscape

The nucleic acid-based therapeutics market is moderately fragmented, with numerous global and regional players actively researching and developing therapeutics for chronic, genetic, and infectious diseases. Notable participants include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Moderna Inc., 诺华公司, Sarepta Therapeutics Inc., Silence Therapeutics PLC, Stoke Therapeutics Inc., and Wave Life Sciences Ltd.

Recent Industry Developments

In March 2023, Ionis Pharmaceuticals received FDA approval for potential accelerated approval of Tofersen for SOD1-ALS treatment. Tofersen reduces SOD1 protein synthesis.

In February 2023, Myeloid Therapeutics Inc. collaborated with the NSW Government in Australia to establish a GMP manufacturing facility for RNA immunotherapies. The facility will expedite commercialization of Myeloid’s RNA therapeutics and promote RNA ecosystem growth in NSW.

Why Buy This Report?

Get a detailed picture of the Global Nucleic Acid Based Therapeutics Market
Identify segments/areas to invest in over the forecast period in the Global Nucleic Acid Based Therapeutics Market
了解竞争环境, 市场的领先参与者
Excel 格式的跨场景分析易用性的市场预估
三个月的战略咨询和研究支持
为单用户许可证提供打印验证